





Community BioRefineries
The Epitome of American Innovation



By Scott Hewitt CEO and Vincent R. James Ph.D. CTO
Community BioRefineries,

Breaking the Chains of Opioid Dependence: Community BioRefinery's Game-Changing Cannabinoid Solution

The opioid crisis represents one of the most significant public health emergencies of our time, with millions of individuals and their families devastated by the consequences of opioid addiction. As the crisis continues to escalate, there is an urgent need for innovative, effective, and sustainable solutions. Community BioRefinery (CBR) is at the forefront of addressing this crisis through its pioneering work in biofuels, sustainable aviation fuel (SAF), green electricity, and the development of the world's first true plant protein isolate. Among these advancements, one of the most promising contributions is the isolation of specific cannabinoids from Industrial Hemp feedstocks. This novel approach has the potential to significantly impact the management of opioid dependence and withdrawal by leveraging the therapeutic benefits of cannabinoids.



The Potential of Cannabinoids in Opioid Addiction Management

Cannabis and its key compounds, particularly cannabidiol (CBD), have attracted considerable attention in recent years for their potential in managing opioid dependence. This interest is supported by a growing body of research

demonstrating the therapeutic benefits of cannabinoids in reducing opioid cravings and managing withdrawal symptoms.

A study conducted by researchers at the University of Southern California found that opioid-dependent individuals who used cannabis reported a noticeable reduction in their cravings and withdrawal symptoms. This study, which focused on people who inject drugs (PWID), underscores the potential of cannabis as an effective harm-reduction tool (**University of Southern California, 2024**).

The therapeutic potential of cannabinoids extends beyond this single study. A comprehensive review by NORML (**2020**) provides compelling evidence supporting the use of cannabis in treating opioid use disorder (OUD). The review states that "growing pre-clinical and clinical evidence appears to support the use of cannabis... to combat OUD." The evidence demonstrates that cannabis can ease opioid withdrawal symptoms, reduce opioid consumption, ameliorate opioid cravings, prevent relapse, improve treatment retention, and even reduce overdose deaths.

Further supporting this evidence, a study published in the *Journal of the American Medical Association* found that states with medical cannabis laws experienced a 25% reduction in opioid overdose mortality rates compared to states without such laws (**Bachhuber, Saloner, Cunningham, & Barry, 2014**). This significant decrease highlights the potential public health benefits of incorporating cannabis into opioid addiction treatment strategies.

In addition, findings published in the *British Journal of Pharmacology* reinforce the role of cannabinoids in pain management, suggesting that these compounds could serve as an alternative or adjunct to opioid-based treatments. This alternative approach could provide pain relief without the high risk of addiction associated with traditional opioids (**Fine & Rosenfeld, 2013**).

Moreover, a study in *Frontiers in Pharmacology* explored the interactions between cannabinoids and the opioid receptor system. The findings suggest that cannabinoids might reduce opioid tolerance and dependence by modulating the opioid receptor system, further supporting their potential role in addiction treatment (**Scavone, Sterling, & Van Bockstaele, 2013**). Additionally, research published in *Neuropsychopharmacology* highlights the critical role of the endocannabinoid system in modulating the brain's reward circuits, which are often disrupted by opioid use, making it a key target for addiction therapies (**Parsons & Hurd, 2015**).

CBR's Cannabinoid Isolation Process

Community BioRefinery has harnessed the potential of cannabinoids through a cutting-edge process that isolates these compounds from various plant feedstocks. CBR's proprietary biorefinery process is designed to extract high-value compounds such as cannabinoids in their most potent and pure form, ensuring maximum therapeutic benefits.

The process is both environmentally friendly and sustainable, utilizing diverse plant materials without the need for harmful chemicals or excessive heat. This approach preserves the integrity of the cannabinoids and aligns with CBR's broader commitment to sustainability and holistic health solutions.

Choosing the Best Form for Cannabinoid Delivery

After isolating specific cannabinoids, determining the best form for their use depends on the intended application, target market, and desired onset and duration of effects. The following are common forms in which cannabinoids can be delivered, each with its advantages:

1. Pill Form (Capsules/Tablets)

- **Advantages:** Precise control over dosage, convenience, discreetness, and longer shelf life. Pills offer a controlled and consistent dosage, making them ideal for clinical or therapeutic applications where accuracy is critical.
- **Best For:** Patients or consumers seeking consistent and controlled dosing, particularly in clinical settings.

2. Oils

- **Advantages:** Versatility in application, quick absorption when taken sublingually, and customizable dosing. Oils can be used sublingually, added to food or beverages, or applied topically, providing users with flexible options.
- **Best For:** Users who require versatile application methods or need fast-acting relief or therapeutic effects.

3. Gummies

- **Advantages:** Palatable, discreet, convenient, and offer controlled dosing. Gummies are enjoyable to consume and easy to monitor in terms of intake, making them appealing to a broad audience.
- **Best For:** Casual users, those new to cannabinoids, and individuals who prefer a tasty and easy-to-consume form.

For clinical or therapeutic use, capsules or tablets may be the best option due to their precise dosing and stability. Oils are ideal for users who prefer versatility and quick absorption, while gummies offer a more enjoyable experience for those looking for convenience and taste. Ultimately, the best form will depend on the specific needs of the target audience and the desired outcomes from the cannabinoid product.

Nutraceuticals: The Future of Addiction Treatment

Nutraceuticals—bioactive compounds derived from natural sources that promote health and prevent disease—are central to CBR's mission to create sustainable, plant-based solutions for modern health challenges. By incorporating isolated cannabinoids into nutraceutical products, CBR opens new avenues for addiction treatment that are both effective and environmentally responsible.

These nutraceuticals serve as natural alternatives to traditional opioid addiction treatments, offering a pathway to recovery that aligns with the latest research on the benefits of cannabis and CBD. As the body of evidence supporting these benefits continues to grow, CBR remains at the forefront of developing products that can make a significant impact on the lives of those affected by opioid dependence.

Conclusion

The opioid crisis requires innovative and sustainable solutions to alleviate its devastating impact on individuals and communities. Community BioRefinery's work in isolating cannabinoids presents a promising avenue for the management of opioid dependence and withdrawal. Through its commitment to harnessing the potential of cannabinoids, CBR offers a variety of nutraceutical products designed to support those struggling with addiction, providing natural and effective alternatives to traditional treatments. As CBR continues to explore and develop these solutions, the future of addiction treatment may increasingly rely on the therapeutic power of plant-based compounds.

SEE: www.communitybiorefineries.com

References

Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA Internal Medicine*, 174(10), 1668-1673.

Fine, P. G., & Rosenfeld, M. J. (2013). The endocannabinoid system, cannabinoids, and pain. *Rheumatology (Oxford, England)*, 52(12), 1920-1928.

NORML. (2020). *Relationship Between Marijuana and Opioids*. NORML Fact Sheet.

Parsons, L. H., & Hurd, Y. L. (2015). Endocannabinoid signaling in reward and addiction. *Neuropsychopharmacology*, 40(1), 163-177.

Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013). Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal. *Frontiers in Pharmacology, 4*(60).

University of Southern California. (2024). *Cannabis co-use as a facilitator of decreased opioid use among people who inject drugs in Los Angeles, California.* Drug and Alcohol Dependence Reports.